0001415889-24-020106.txt : 20240725
0001415889-24-020106.hdr.sgml : 20240725
20240725163239
ACCESSION NUMBER: 0001415889-24-020106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240723
FILED AS OF DATE: 20240725
DATE AS OF CHANGE: 20240725
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ragosa Mark
CENTRAL INDEX KEY: 0001835458
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38492
FILM NUMBER: 241142503
MAIL ADDRESS:
STREET 1: C/O KINIKSA PHARMACEUTICALS CORP.
STREET 2: 100 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc
CENTRAL INDEX KEY: 0001730430
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 23 OLD BOND STREET, FLOOR 3
CITY: LONDON
STATE: X0
ZIP: WIS 4PZ
BUSINESS PHONE: 7814319100
MAIL ADDRESS:
STREET 1: 23 OLD BOND STREET, FLOOR 3
CITY: LONDON
STATE: X0
ZIP: WIS 4PZ
FORMER COMPANY:
FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd.
DATE OF NAME CHANGE: 20180205
4
1
form4-07252024_080736.xml
X0508
4
2024-07-23
0001730430
Kiniksa Pharmaceuticals International, plc
KNSA
0001835458
Ragosa Mark
23 OLD BOND STREET, THIRD FLOOR
LONDON
X0
W1S 4PZ
UNITED KINGDOM
false
true
false
false
CHIEF FINANCIAL OFFICER
1
Class A Ordinary Share
2024-07-23
4
M
0
24248
11.10
A
43501
D
Class A Ordinary Share
2024-07-23
4
S
0
24248
24.79
D
19253
D
Share Option
11.10
2024-07-23
4
M
0
24248
0
D
2032-04-06
Class A Ordinary Share
24248
40412
D
This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.
This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.72 and $25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
/s/ Madelyn Zeylikman, Attorney-in-Fact
2024-07-25